- Report
- April 2022
- 85 Pages
Global
From €3500EUR$4,188USD£3,086GBP
- Report
- April 2022
- 92 Pages
Global
From €3500EUR$4,188USD£3,086GBP
- Report
- December 2022
- 35 Pages
Global
From €1790EUR$2,000USD£1,525GBP
- Report
- October 2022
- 1127 Pages
Global
From €2238EUR$2,500USD£1,906GBP
- Report
- October 2022
- 548 Pages
Global
From €2238EUR$2,500USD£1,906GBP
- Report
- January 2025
- 132 Pages
Global
From €850EUR$950USD£724GBP
- Report
- March 2024
- 132 Pages
Global
From €850EUR$950USD£724GBP
- Report
- June 2023
- 132 Pages
Global
From €850EUR$950USD£724GBP
The Antidiabetic market is a subset of Endocrine and Metabolic Disorders Drugs, which are used to treat a variety of conditions related to hormones and metabolism. Antidiabetic drugs are used to treat diabetes, a chronic condition in which the body does not produce or properly use insulin. These drugs can help control blood sugar levels, reduce the risk of complications, and improve quality of life. Common antidiabetic drugs include insulin, sulfonylureas, biguanides, thiazolidinediones, and meglitinides.
Some companies in the Antidiabetic market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. These companies produce a variety of antidiabetic drugs, including insulin, oral medications, and combination products. Show Less Read more